June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

Roche confirms full-year 2016 outlook as first-quarter sales beat forecast

Published 19/04/2016, 06:15
© Reuters. Roche Bactrim tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot in Zenica
ROG
-

ZURICH (Reuters) - Swiss drugmaker Roche (S:ROG) reiterated on Tuesday that it expects to achieve its full-year targets after sales during the first three months of 2016 rose 4 percent, beating analyst expectations.

The Basel-based company expects sales to grow in the low- to mid-single-digit percentages at constant exchange rates, with faster growth of core earnings per share. It plans to boost its dividend in Swiss francs.

© Reuters. Roche Bactrim tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot in Zenica

In a statement, Roche said first-quarter sales rose to 12.4 billion Swiss francs (8.9 billion pounds) compared to the 12.3 billion francs forecast by analysts in a Reuters poll.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.